Upgrade to SI Premium - Free Trial

Wells Fargo Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)

July 21, 2025 5:50 AM
Wells Fargo analyst Yanan Zhu reiterated an Overweight rating and $65.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles